While IA1 and IA2 stimulated similar proliferative effects (12.2 ± 1.2 and 10.7 ± 0.5%, respectively), their impacts on CD4/CD8 differentiation (Fig. 2) were vastly different and, as observed in our previous study, IA1 and IA2 exhibited distinct biological activities and anti-cancer mechanisms (Scott et al. 2019; Wang et al. 2015; Yang et al. 2019). This evidence concerns the gene CD8A and cancer.